Ardea Biosciences Inc

Entity type image
Type: Company
Name: Ardea Biosciences Inc
First reported 20 hours ago - Updated 20 hours ago - 1 reports

Ardea Biosciences, Inc.: New Ardea Biosciences, Inc. company profile published

Ardea Biosciences, Inc. (Ardea) is a biotechnology company. It focuses on the development of small molecules as a novel therapeutics for the treatment of gout and cancer. The product portfolio of the company includes three pipeline products, namely, Lesinurad ... [Published TransWorldNews - 20 hours ago]
First reported May 06 2013 - Updated May 06 2013 - 1 reports

bluebird bio Appoints Two New Members to Its Board of Directors Wendy Dixon, Ph.D., and David Schenkein, M.D.

CAMBRIDGE, Mass. - (BUSINESS WIRE) - bluebird bio, a clinical-stage biotechnology company focused on transforming the lives of patients with severe genetic and orphan diseases using gene therapy, today announced that Wendy Dixon, Ph.D., and David Schenkein, ... [Published NewsBlaze - May 06 2013]
First reported May 02 2013 - Updated May 03 2013 - 3 reports

A.P. Pharma: Management Change Is A Positive For The Stock

IntroductionThis report deals with the just announced management change at A.P. Pharma (APPA.OB) and the positive impact that I believe it will have on the stock. It does not get into an in-depth discussion of the fundamentals and financial projections ... [Published Seeking Alpha - May 03 2013]

Quotes

...discovered and developed 10 approved drugs representing over $5 billion in 2012 sales," said Jonathan Lim, M D , chairman and CEO of Ignyta. "Actagene’s R&D team complements Ignyta’s existing team, platform and capabilities, such as whole genome methylation analysis, next generation sequencing, Methylome™ database, and bioinformatics expertise. This transaction reshapes us into a seamless Rx/Dx company pursuing a significant growth area of patient stratification and targeted drug discovery and development for cancer patients."
Ignyta Announces Acquisition of Actagene Oncology and Entry into Oncology Personalized Medicine [Published Business Wire - May 20 2013]
"We are delighted to welcome Dr. Dixon and Dr. Schenkein to our board," said Nick Leschly, chief bluebird. "Both have demonstrated clear leadership and expertise within their respective fields. Wendy has extensive experience in all aspects of drug commercialization, while David has a proven track record in innovative oncology drug development and hematologic transplantation. Their experiences will be invaluable to bluebird as we advance multiple gene therapy programs towards the market."
bluebird bio Appoints Two New Members to Its Board of Directors Wendy Dixon, Ph.D., and David Sch ... [Published Pharmacy Choice - May 20 2013]
...trial of EDI200 and we will soon be recruiting subjects for the Phase 2 neonate trial," said Neil Kirby, Ph D , President and CEO of Edimer. "We enthusiastically welcome Bill and Wendy to the Board. I am confident that their broad expertise and experience will be of tremendous value as we enter the next phase of Edimer's development."
Edimer Names William Aliski and Wendy L. Dixon to Board [Man. . . [Published Equities.com - May 08 2013]
...APF530, and capitalize on the Company's Biochronomer? drug delivery platform," said Kevin C Tang, Chairman of the A P Pharma Board of Directors. "Barry was instrumental in building two biopharmaceutical companies, Ardea Biosciences and Agouron Pharmaceuticals, that were acquired by major pharmaceutical companies for more than $1 billion each. Rob brings deep experience in the commercialization of oncology drugs and was responsible for the launch of two products, Nexavar and Eloxatin, that each achieved sales of more than $1 billion only a few years following market introduction. Steve most recently was the chief architect in the transaction resulting in the sale of Ardea Biosciences to AstraZeneca for more than $1 billion."
A.P. PHARMA, INC.: A.P. Pharma Appoints New Management Team [Published 4 Traders - May 02 2013]

More Content

All (16) | News (10) | Reports (1) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
Ardea Biosciences, Inc.: New Ardea Biosciences,... [Published TransWorldNews - 20 hours ago]
Ignyta Announces Acquisition of Actagene Oncolo... [Published Business Wire - May 20 2013]
bluebird bio Appoints Two New Members to Its Bo... [Published Pharmacy Choice - May 20 2013]
bluebird bio Appoints Two New Members to Its Bo... [Published Equities.com - May 15 2013]
Edimer Names William Aliski and Wendy L. Dixon ... [Published Equities.com - May 08 2013]
bluebird bio Appoints Two New Members to Its Bo... [Published NewsBlaze - May 06 2013]
bluebird bio Appoints Two New Members to Its Bo... [Published Business Wire - May 06 2013]
A.P. Pharma: Management Change Is A Positive Fo... [Published Seeking Alpha - May 03 2013]
A.P. PHARMA, INC.: A.P. Pharma Appoints New Man... [Published 4 Traders - May 02 2013]
Edimer Appoints William Aliski and Wendy L. Dix... [Published Zecco - May 02 2013]
A.P. Pharma Appoints New Management Team [Published Zecco - May 02 2013]
AstraZeneca's PhIII chief scouts for blockbuste... [Published FierceBiotech - Apr 25 2013]
Antiretroviral Therapy Update From the 48th ICA... [Published The AIDS Reader - Apr 18 2013]
DOTW: Wall Street Hopes AstraZeneca is the Next... [Published The IN VIVO Blog - Jan 18 2013]
M&A Deal of the Year Nominee Bristol-Myers/Amyl... [Published The IN VIVO Blog - Dec 18 2012]
GlobalSubmit Opens New Office in San Diego, Ann... [Published PR Newswire - Aug 16 2012]
1
In Focus
  •  
Steve Davis, Robert Rosen, Michael Rice, [more]
  •  
AP Pharma Inc, AstraZeneca PLC, Pfizer Inc, [more]
  •  
Southern Nazarene University, Northeastern University, Vanderbilt University, [more]
  •  
Oncology, complete response, Drugs, [more]
  •  
Lesinurad, Eloxatin, Nexavar, [more]
  •  
San Diego (California, United States), San Francisco (United States), Philadelphia (Pennsylvania, United States), [more]
  •  
England, United States, Japan, [more]
  •  
Diseases, Epidemics, Medication, [more]
  •  
Banking & Financial Services, Health, Pharma & Biotech
TransWorldNews, Seeking Alpha, Zecco, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
DOTW: Wall Street Hopes AstraZeneca is the Next... [Published The IN VIVO Blog - Jan 18 2013]
Wall Street is hoping AstraZeneca will buy its way out of its current conundrum. The pharma jumped off the proverbial patent cliff last year and is expected to slide for the foreseeable future. Analysts' model for a turnaround of the beleaguered British ...
M&A Deal of the Year Nominee Bristol-Myers/Amyl... [Published The IN VIVO Blog - Dec 18 2012]
It's time for the IN VIVO Blog's Fifth Annual Deal of the Year! competition. This year we're once again presenting awards in three categories to highlight the most interesting and creative deal making solutions of the year. The categories are: M&A ...
1

Press Releases

sort by: Date | Relevance
Ignyta Announces Acquisition of Actagene Oncolo... [Published Business Wire - May 20 2013]
bluebird bio Appoints Two New Members to Its Bo... [Published Business Wire - May 06 2013]
GlobalSubmit Opens New Office in San Diego, Ann... [Published PR Newswire - Aug 16 2012]
1
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.